What is the clinical evidence from this study?

Study design: Cohort. Population: Soft tissue sarcoma (n=32). Intervention: Dexrazoxane and high-dose anthracycline. Primary outcome: Anthracycline-induced cardiotoxicity in patients without preexisting major cardiac findings.

August 9, 2016BMC CancerOpen Access

Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy – a retrospective study including 32 patients

View Full Paper

Ask AI

Bookmark

Key result

Coadministration of dexrazoxane with high cumulative doses of anthracyclines in advanced sarcoma patients resulted in a 7% rate of cardiotoxicity and a median overall survival of 17 months.

Why the study?

Does dexrazoxane prevent anthracycline-induced cardiotoxicity in sarcoma patients receiving high cumulative doses of anthracycline therapy?

Population

32 patients with soft tissue sarcoma and metastatic or advanced disease treated with doxorubicin and…

Design

Cohort

Follow-up

until death or last patient contact

Authors

MSMarkus K. SchulerStiftung Oskar Helene Heim SGSebastian GerdesUniversity Hospital Carl Gustav Carus AWAntje WestHelios Hospital Bad Saarow

Discussion

Member takes

Implication

May support dexrazoxane to limit cardiotoxicity during high-dose anthracycline sarcoma therapy; leaves open randomized confirmation.

Study Design

Type

Cohort (n=32)

Multicenter

Yes

Structured PICO

Does dexrazoxane prevent anthracycline-induced cardiotoxicity in sarcoma patients receiving high cumulative doses of anthracycline therapy?

Population

32 adult patients with advanced or metastatic soft tissue sarcoma receiving high cumulative doses of anthracyclines in combination with dexrazoxane, evaluated retrospectively.

Exposure

Dexrazoxane (DRZ) given intravenously 30 min before doxorubicin over 15 min in tenfold concentration compared with doxorubicin dosage, in combination with doxorubicin-based chemotherapy (doxorubicin 60-75 mg/m2 day 1 and dacarbazine 400 mg/m2 day 1-3).

Outcome

Anthracycline-induced cardiotoxicity (defined as new onset of symptoms of heart failure, new hypokinesia, drop in LVEF below 50%, or decrease of more than 10% from basal value) and overall survival.safety

Coadministration of dexrazoxane allows sarcoma patients to safely receive high cumulative doses of anthracyclines with a low rate of cardiotoxicity and promising overall survival.

Limitations

Retrospective data collection
Small sample size from only four institutions
Potential selection bias
Lack of standardized criteria for the timing and reason of dexrazoxane introduction
Availability of newer therapeutic options beyond doxorubicin
Retrospective data collection from only four institutions
Time and reason of introduction of DRZ in an ongoing regimen or upon rechallenge were not clearly defined
Current availability of more therapeutic options beyond doxorubicin

Cite This Study

Schuler et al. (2016) conducted a cohort in Soft tissue sarcoma (n=32). Dexrazoxane and high-dose anthracycline was evaluated on Anthracycline-induced cardiotoxicity in patients without preexisting major cardiac findings. Coadministration of dexrazoxane with high cumulative doses of anthracyclines in advanced sarcoma patients resulted in a 7% rate of cardiotoxicity and a median overall survival of 17 months.

synapsesocial.com/papers/6a21008bd7fc0b4ba5f646ff https://doi.org/10.1186/s12885-016-2654-x

View Full Paper

Ask AI

Bookmark

Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy – a retrospective study including 32 patients

Discussion

Member takes

Implication

Study Design

Structured PICO

Limitations

Cite This Study

Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy – a retrospective study including 32 patients

Discussion

Member takes

Implication

Study Design

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider